According to the report
analysis, ‘Liquid
Biopsy Market - Global Drivers, Restraints, Opportunities, Trends, and
Forecasts: 2017-2023’ states that there are several key players which recently
performing in the liquid biopsy market across the globe for leading the fastest
market growth and registering the high value of revenue throughout the short
span of time while decreasing the cost of test with growth in reimbursement
facilities, deduction in ethical issues and effective increasing the skilled
professional for functioning advanced diagnostics testing involves Biocept,
Inc, F- Hoffmann-la Roche, Illumina, Inc, NateraInc, Trovagene Inc., Qiagen
N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute,
Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc.,
Myriad Genetics, Inc., and several other predominate & niche players.
The liquid biopsy market
has boomed up owing to the effective rise in the prevalence of cancer across
the globe, developed maternal age prominent to increasing chromosomal
aberrations, and the effective augment in the preference of non-invasive liquid
biopsy tests over the invasive tissue biopsy. Whereas, the liquid biopsy is an
insignificantly and non-invasive technology that monitors molecular biomarkers
utilizing the liquid sample without the requirement of the expensive or
invasive processes. Such tests have considerable potential for the early
monitor of cancer, treatment and reappearance observing, detection of genetic
irregularities in the fetus, and graft denunciation in the transplantation
patients.
In addition, According to
the Canadian Cancer Society, 202,400 novel cases of cancer and approximately
78,000 deaths are predicted in 2016. While in Europe 1.3 million people were established
in 2015. Further, according to the study of World Health Organization, almost
14 million new cancer circumstances were detected and is predictable to augment
by approximately 70% over the coming 2 decades.
The Global Liquid Biopsy
Market is predictable to observe a CAGR of 24.1% during the forecast period of
2017-2023. However, the market of liquid biopsy is sectored into different
regions which majorly involves North America, Europe, Asia Pacific, and Rest of
the World (RoW). The Americas is set to be the leading region for the liquid
biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the
unindustrialized regions.
Additionally, based on the
application, the global liquid biopsy market by application is sectored into
cancer and non-cancer applications. The Cancer sector conquers the largest
market share and is anticipated to be the fastest augmenting segment during the
forecasted period. Cancer application is further sectored by the cancer
indication and clinical application. Furthermore, on the basis of end-user, the
global liquid biopsy market by end-users is sectored into hospital and
reference laboratories, academic and research institutes, and several others.
Hospital and reference laboratories employed a foremost share of liquid biopsy
market in 2016 owing to the growing volume of test mockups outsourced to this
sector.
In the recent times, the
cancer tests account the global liquid biopsy market. A lot of fresh players
are thinking more significantly on this market to deliver the ground-breaking
test with great sensitivity, specificity, and low turnaround time. The foremost
market players are attaining the small companies to deliver their product
portfolio and support their leadership position across the market. Therefore,
in the near future, it is predicted that the market of liquid biopsy will
increase around the globe more significantly over the coming decades.
For more information on the research
report, refer to below link:
Related Reports
Contact Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment